Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer

Despite the development of advanced therapeutic regimens such as molecular targeted therapy and immunotherapy, the 5-year survival of patients with lung cancer is still less than 20%, suggesting the need to develop additional treatment strategies. The molecular chaperone heat shock protein 90 (Hsp90...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Seung Yeob, Le, Huong Thuy, Nguyen, Cong-Truong, Yong, Young-Sik, Boo, Hye-Jin, Lee, Ho Jin, Lee, Ji-Sun, Min, Hye-Young, Ann, Jihyae, Chen, Jie, Park, Hyun-Ju, Lee, Jeewoo, Lee, Ho-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141536/
https://www.ncbi.nlm.nih.gov/pubmed/30224681
http://dx.doi.org/10.1038/s41598-018-32196-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141536/
https://www.ncbi.nlm.nih.gov/pubmed/30224681
http://dx.doi.org/10.1038/s41598-018-32196-6

Ejemplares similares